<DOC>
	<DOCNO>NCT01468129</DOCNO>
	<brief_summary>This study investigate efficacy use cell saver bilater total hip arthroplasty</brief_summary>
	<brief_title>Cell Saver Use Bilateral Total Hip Arthroplasty ( THA )</brief_title>
	<detailed_description />
	<criteria>Subject 21 year age Subject bilateral degenerative disease hip candidate onestage bilateral THA Subject willing able provide write informed consent Subject significant comorbidities identify Charleston index â‰¥ 3 Subject malignancy Subject history heart disease , myocardial infarction , pulmonary insufficiency , pulmonary embolus , document fat emboli syndrome , adult respiratory distress syndrome , document patent ductus arteriosus septal defect , chronic renal failure and/or acute hepatic failure chirhosis Subjects hematologic disorder anemia ( Hb &lt; 10 g/dL ) sickle cell disease , acquire congenital coagulopathies , acquire congenital bleeding disorder , Subject receive anticoagulant aspirin Warfarin ( Coumadin ) antiplatelet agent clopidogrel ( Plavix ) within 7 day surgery Subject receive hemostatic agent tranexamic acid aprotinin Subjects utilize acute normovolumic haemodilution Subject permit remain without his/her anticoagulant regimen ( eg Plavix ) 48 hour postoperatively Subject know pregnant . Subject erythropoietin agonist/stimulating agent within 90 day prior surgery . Presence contaminant urine , fat , bowel content , importantly infection operative field Presence vasoactive drug papaverine operative field</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>